MRUS Stock - Merus N.V.
Unlock GoAI Insights for MRUS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $34.88M | $39.81M | $38.84M | $43.15M | $24.51M |
| Gross Profit | $12.96M | $29.31M | $28.88M | $-43,121,688 | $-32,823,404 |
| Gross Margin | 37.2% | 73.6% | 74.4% | -99.9% | -133.9% |
| Operating Income | $-262,626,275 | $-141,800,272 | $-149,459,488 | $-79,052,913 | $-62,113,730 |
| Net Income | $-207,854,187 | $-140,343,746 | $-122,522,076 | $-58,704,537 | $-70,000,941 |
| Net Margin | -595.9% | -352.6% | -315.5% | -136.1% | -285.6% |
| EPS | $-3.35 | $-3.00 | $-2.92 | $-1.73 | $-2.92 |
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Visit WebsiteEarnings History & Surprises
MRUSEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Oct 31, 2025 | $-1.23 | $-1.23 | 0.0% | = MET |
Q3 2025 | Aug 5, 2025 | $-1.17 | $-2.23 | -90.6% | ✗ MISS |
Q2 2025 | May 7, 2025 | $-1.16 | $-1.40 | -20.7% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $-0.89 | $-0.41 | +53.9% | ✓ BEAT |
Q4 2024 | Oct 31, 2024 | $-0.90 | $-0.95 | -5.6% | ✗ MISS |
Q3 2024 | Aug 1, 2024 | $-0.76 | $-0.81 | -6.6% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-0.81 | $-0.59 | +27.2% | ✓ BEAT |
Q1 2024 | Feb 28, 2024 | $-0.74 | $-1.04 | -40.5% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $-0.73 | $-0.43 | +41.1% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $-0.88 | $-0.66 | +25.0% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-1.02 | $-0.86 | +15.7% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $-0.83 | $-1.81 | -118.1% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-0.63 | $-0.53 | +15.9% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-0.62 | $-0.13 | +79.0% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $-0.62 | $-0.43 | +30.6% | ✓ BEAT |
Q1 2022 | Feb 28, 2022 | $-0.58 | $-0.34 | +41.4% | ✓ BEAT |
Q4 2021 | Nov 2, 2021 | $-0.62 | $-0.39 | +37.1% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-0.59 | $-0.71 | -20.3% | ✗ MISS |
Q2 2021 | May 6, 2021 | $-0.24 | $-0.28 | -16.7% | ✗ MISS |
Q1 2021 | Mar 16, 2021 | $-0.61 | $-0.77 | -26.2% | ✗ MISS |
Latest News
Frequently Asked Questions about MRUS
What is MRUS's current stock price?
What is the analyst price target for MRUS?
What sector is Merus N.V. in?
What is MRUS's market cap?
Does MRUS pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to MRUS for comparison